Skip to main content
Terug
GZPHF logo

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Datakwaliteit: 100%
Overbought
GZPHF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 2,34
▼ € 0,20 (-8,55%)
Marktkapitalisatie: 5,93B
Dagbereik
€ 2,34 € 2,34
52-Weeksbereik
€ 2,14 € 2,88
Volume
300
50D / 200D Gem.
€ 2,26 / € 2,31
Vorige Slotkoers
€ 2,34

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 2,0 0,4
P/B 0,2 2,9
ROE % 7,9 3,8
Net Margin % 3,9 3,9
Rev Growth 5Y % 2,3 10,0
D/E 0,6 0,2

Belangrijkste Punten

Revenue grew 2,25% annually over 5 years — modest growth
Negative free cash flow of -954,41M
P/E of 2,04 — trading at a low valuation
Capital efficient — spends only 1,60% of revenue on capex
ROIC of 3,87% — low return on invested capital

Groei

Revenue Growth (5Y)
2,25%
Revenue (1Y)0,61%
Earnings (1Y)2,49%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
7,89%
ROIC3,87%
Net Margin3,85%
Op. Margin4,01%

Veiligheid

Debt / Equity
0,55
Current Ratio1,57
Interest Coverage7,26

Waardering

P/E Ratio
2,04
P/B Ratio0,16
EV/EBITDA3,87
Dividend Yield0,05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0,61% Revenue Growth (3Y) -0,05%
Earnings Growth (1Y) 2,49% Earnings Growth (3Y) -15,35%
Revenue Growth (5Y) 2,25% Earnings Growth (5Y) -5,99%
Profitability
Revenue (TTM) 75,45B Net Income (TTM) 2,91B
ROE 7,89% ROA 3,44%
Gross Margin 15,18% Operating Margin 4,01%
Net Margin 3,85% Free Cash Flow (TTM) -954,41M
ROIC 3,87% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,55 Current Ratio 1,57
Interest Coverage 7,26 Dividend Yield 0,05%
Valuation
P/E Ratio 2,04 P/B Ratio 0,16
P/S Ratio 0,08 PEG Ratio 1,82
EV/EBITDA 3,87 Dividend Yield 0,05%
Market Cap 5,93B Enterprise Value 11,69B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 75,45B 74,99B 75,52B 70,79B 69,01B
Net Income 2,91B 2,84B 4,06B 3,97B 3,72B
EPS (Diluted) 1,82 1,74 2,49 2,44 2,29
Gross Profit 11,46B 12,52B 14,19B 13,28B 13,23B
Operating Income 3,02B 3,60B 5,12B 5,07B 4,79B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 84,55B 81,68B 78,59B 74,67B 66,12B
Total Liabilities 43,41B 43,91B 41,91B 41,03B 34,79B
Shareholders' Equity 37,81B 35,90B 34,92B 32,07B 29,06B
Total Debt 20,70B 12,37B 11,70B 11,43B 9,92B
Cash & Equivalents 14,95B 18,27B 21,31B 22,50B 22,38B
Current Assets 61,55B 57,76B 55,98B 57,06B 52,81B
Current Liabilities 39,14B 38,92B 36,24B 37,40B 32,25B